ANTH OTC
Anthera Pharmaceuticals, Inc.
1W: -0.0%
1M: +0.0%
3M: -90.0%
YTD: -0.0%
1Y: +0.0%
3Y: -0.0%
5Y: -99.8%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
-$281K
-384.6% ▼
Operating Income
-$36M
+36.3% ▲
Net Income
-$17M
+68.4% ▲
EPS (Diluted)
$-1.65
+84.1% ▲
EBITDA
-$27M
+53.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3M | $145K | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | -95.4% | -100.0% |
| Cost of Revenue | $22K | $22K | $31K | $46K | $281K |
| Gross Profit | -$22K | -$22K | $3M | $99K | -$281K |
| Gross Margin | — | — | 99.0% | 68.1% | — |
| R&D Expenses | $22M | $22M | $31M | $46M | $29M |
| SG&A Expenses | $7M | $7M | $8M | $11M | $8M |
| Operating Expenses | $28M | $28M | $38M | $57M | $37M |
| Operating Income | -$28M | -$28M | -$35M | -$57M | -$36M |
| Operating Margin | — | — | -1106.5% | -39432.4% | — |
| Interest Expense | $3M | $1M | $0 | $0 | $0 |
| Income Before Tax | -$31M | -$30M | -$35M | -$56M | -$27M |
| Tax Expense | $0 | $0 | -$308K | -$2M | $0 |
| Net Income | -$33M | -$30M | -$35M | -$54M | -$17M |
| Net Margin | — | — | -1096.1% | -36967.6% | — |
| EPS (Diluted) | $-14.50 | $-11.13 | $-7.84 | $-10.38 | $-1.65 |
| EBITDA | -$28M | -$28M | -$35M | -$57M | -$27M |
| Shares Outstanding | 2M | 3M | 4M | 5M | 10M |